CD7 and neoplasm: To evaluate the ability of αCD7/EVs to target CD7+ tumours in vivo, VivoTrack 680‐labelled Ctrl/EVs and αCD7/EVs were intravenously injected in Molt‐4/Raji subcutaneous (s.c.)tumour‐bearing mice.